アトピー性皮膚炎治療薬のアジア市場

【英語タイトル】ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET FORECAST 2018-2026

Inkwood Researchが出版した調査資料(INKW807113)・商品コード:INKW807113
・発行会社(調査会社):Inkwood Research
・発行日:2018年4月16日
・ページ数:76
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:アジア、日本、中国
・産業分野:PHARMACEUTICALS
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥130,000見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥156,000見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

KEY FINDINGSThe Atopic Dermatitis Drugs market in APAC region is anticipated to evolve at a CAGR of 7.46% over the estimated period 2018-2026. The region is the growing with the highest growth rate as Atopic Dermatitis is the most common skin disease in the region which is also further boosting the demand of the market in this region.
MARKET INSIGHTS
The major countries present in the Atopic Dermatitis Drugs market are India, China, Australia, South Korea, New Zealand, Japan and rest of APAC. The high prevalence of Atopic Dermatitis are seen in countries like China, India, and Malaysia. The route of administration (ROD) of this disease is done in three ways topical, oral, and injectable. Out of which, topical is the most popular route of administration in the market. Another segment present in the Atopic Dermatitis Drug market is drug class. Japan and India are the two countries contributing highest and growing with the highest CAGR over the forecast period.
COMPETITIVE INSIGHTS
The dominating players in APAC market are Aqua Pharmaceuticals (An Almirall Company), Galderma SA, Valent Pharmaceutical Inc., Novartis Ag, Leo Pharma, Meda Pharmaceuticals (Mylan), Astellas Pharma Inc., Astellas Pharma Inc., Bristol-Myers Squibb, Pfizer, Regeneron Pharmaceuticals, Stiefel Laboratories Inc., Allergan Plc, Sanofi SA, Encore Dermatology, and Bayer Ag.

【レポートの目次】

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP-DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. TOPICAL ROUTE OF ADMINISTRATION HOLDS MAJORITY SHARE IN THE OVERALL MARKET
3.2.2. INTERLEUKIN INHIBITOR MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE
4. MARKET DYNAMICS
4.1. INTRODUCTION: ATOPIC DERMATITIS
4.2. MARKET DEFINITION & SCOPE
4.3. LEGAL, POLICY AND REGULATORY ISSUES
4.4. MARKET DRIVERS
4.4.1. GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
4.4.2. GROWING FOCUS ON SYSTEMATIC THERAPIES
4.4.3. INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
4.5. MARKET RESTRAINTS
4.5.1. STRINGENT REGULATIONS FOR PRODUCT APPROVAL
4.5.2. GENERIC COMPETITION
4.6. MARKET OPPORTUNITIES
4.6.1. INCREASING M&A LEADING TO MARKET CONSOLIDATION
4.6.2. LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
4.6.3. GROWING FOCUS ON NOVEL DRUGS
4.7. MARKET CHALLENGES
4.7.1. BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
4.7.2. HIGHLY GENERCIZED MARKET
4.7.3. POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE
5. MARKET BY ROUTE OF ADMINISTRATION (ROA)
5.1. TOPICAL
5.2. ORAL
5.3. INJECTABLE
6. MARKET BY DRUG CLASS
6.1. TOPICAL ANTIBIOTICS
6.2. TOPICAL ANTIHISTAMINES
6.3. TOPICAL CORTICOSTEROIDS
6.4. TOPICAL MOISTURIZERS/EMOLLIENTS
6.5. TOPICAL CALCINEURIN INHIBITORS
6.6. IMMUNOMODULATORS
6.7. OFF-LABEL THERAPIES
6.8. SYSTEMIC AGENTS
6.9. PDE-4 INHIBITOR
6.10. INTERLEUKIN INHIBITOR
7. KEY ANALYTICS
7.1. PORTERS FIVE FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTE
7.1.3. BARGAINING POWER OF SUPPLIERS
7.1.4. BARGAINING POWER OF BUYERS
7.1.5. THREAT OF COMPETITIVE RIVALRY
7.2. OPPORTUNITY MATRIX
7.3. VENDOR LANDSCAPE
7.4. PIPELINE ANALYSIS
8. GEOGRAPHICAL ANALYSIS
8.1. INDIA
8.2. CHINA
8.3. JAPAN
8.4. AUSTRALIA AND NEW ZEALAND
8.5. SOUTH KOREA
8.6. REST OF ASIA PACIFIC
9. COMPANY PROFILES
9.1. ALLERGAN PLC.
9.2. AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
9.3. ASTELLAS PHARMA INC.
9.4. BAYER AG
9.5. BIOFRONTERA AG
9.6. BRISTOL-MYERS SQUIBB
9.7. STIEFEL LABORATORIES INC
9.8. ENCORE DERMATOLOGY
9.9. GALDERMA SA
9.10. LEO PHARMA
9.11. MEDA PHARMACEUTICALS (MYLAN)
9.12. NOVARTIS AG
9.13. PFIZER
9.14. REGENERON PHARMACEUTICALS
9.15. SANOFI SA
9.16. VALENT PHARMACEUTICAL INC.
LIST OF TABLES
TABLE 1: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY GEOGRAPHY, 2018-2026 (IN $ MILLION)
TABLE 2: REGULATORY FRAMEWORK IN ATOPIC DERMATITIS DRUGS MARKET
TABLE 3: RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET
TABLE 4: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY ROA, 2018-2026, (IN $ MILLION)
TABLE 5: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY DRUG CLASS, 2018-2026 (IN $ MILLION)
TABLE 6: OPPORTUNITY MATRIX FOR ATOPIC DERMATITIS DRUGS MARKET
TABLE 7: VENDOR LANDSCAPE OF ATOPIC DERMATITIS DRUGS MARKET
TABLE 8: PIPELINE PORTFOLIO OF ATOPIC DERMATITIS DRUGS MARKET
TABLE 9: ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY COUNTRY, 2018-2026 (IN $ MILLION)

LIST OF FIGURES
FIGURE 1: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET 2018-2026 (IN $ MILLION)
FIGURE 2: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL ROUTE OF ADMINISTRATION, 2018-2026 (IN $ MILLION)
FIGURE 3: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY INTERLEUKIN INHIBITOR, 2018-2026 (IN $ MILLION)
FIGURE 4: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY ROA, 2017 & 2026 (IN %)
FIGURE 5: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL, 2018-2026 (IN $ MILLION)
FIGURE 6: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY ORAL, 2018-2026 (IN $ MILLION)
FIGURE 7: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY INJECTABLE, 2018-2026 (IN $ MILLION)
FIGURE 8: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY DRUG CLASS, 2017 & 2026 (IN %)
FIGURE 9: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL ANTIBIOTICS, 2018-2026 (IN $ MILLION)
FIGURE 10: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL ANTIHISTAMINES, 2018-2026 (IN $ MILLION)
FIGURE 11: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL CORTICOSTEROIDS, 2018-2026 (IN $ MILLION)
FIGURE 12: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL MOISTURIZERS/EMOLLIENTS, 2018-2026 (IN $ MILLION)
FIGURE 13: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY TOPICAL CALCINEURIN INHIBITORS, 2018-2026 (IN $ MILLION)
FIGURE 14: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY IMMUNOMODULATORS, 2018-2026 (IN $ MILLION)
FIGURE 15: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY OFF-LABEL THERAPIES, 2018-2026 (IN $ MILLION)
FIGURE 16: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY SYSTEMIC AGENTS, 2018-2026 (IN $ MILLION)
FIGURE 17: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY PDE-4 INHIBITOR, 2018-2026 (IN $ MILLION)
FIGURE 18: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, BY INTERLEUKIN INHIBITOR, 2018-2026 (IN $ MILLION)
FIGURE 19: PORTER’S FIVE FORCE MODEL OF ATOPIC DERMATITIS DRUGS MARKET
FIGURE 20: ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, REGIONAL OUTLOOK, 2017 & 2026 (IN %)
FIGURE 21: CHINA ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 22: INDIA ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 23: JAPAN ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 24: AUSTRALIA AND NEW ZEALAND ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 25: SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)
FIGURE 26: REST OF ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET, 2018-2026 (IN $ MILLION)



【レポートのキーワード】

アトピー性皮膚炎治療薬

★調査レポート[アトピー性皮膚炎治療薬のアジア市場] (コード:INKW807113)販売に関する免責事項を必ずご確認ください。
★調査レポート[アトピー性皮膚炎治療薬のアジア市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆